Related Experiment Videos
Do NSAIDs prevent colorectal cancer?
1Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. nadir@tasmc.health.gov.il
Abstract:
There is increasing evidence to suggest that acetylsalicylic acid (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colorectal cancer. This observation is supported by animal studies that show fewer tumours per animal and fewer animals with tumours after administration of several different NSAIDs. Studies in humans consistently support this hypothesis. Intervention data from familial adenomatosis coli establish that the process of human colonic adenoma polyp formation is affected. Supportive evidence comes from 21 of 23 human studies - both case-control and cohort. The reduced risk has been found in men and women, for cancers of the colon and the rectum and for the use of both ASA and the other NSAIDs. Earlier detection of lesions as a result of drug-induced bleeding does not seem to account for these findings. The molecular mechanisms responsible for the chemopreventive action of this class of drugs is not completely established. Protection may affect several pathways, including cell cycle arrest and induction of apoptosis. Because of the consistency of epidemiological, clinical and experimental data, there is no need for further placebo trials. At the same time, there is a need to establish the dose, duration and frequency of use required for cancer-preventive activity.
Insights
Acetylsalicylic acid (ASA) and NSAIDs significantly lower colorectal cancer risk, supported by animal and human studies. Further research is needed to determine optimal dosage for cancer prevention.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Growing evidence suggests acetylsalicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) decrease colorectal cancer risk.
- Both animal models and human studies consistently support this chemopreventive effect.
- Intervention data indicates NSAIDs impact human colonic adenoma polyp formation.
Purpose of the Study:
- To review the evidence for NSAID-induced chemoprevention of colorectal cancer.
- To explore the consistency and scope of findings across different study types and populations.
- To identify the need for further research into optimal dosing and mechanisms.
Main Methods:
- Systematic review of epidemiological, clinical, and experimental data.
- Analysis of human studies including case-control and cohort designs.
- Evaluation of animal studies demonstrating reduced tumor incidence.
Main Results:
- 21 out of 23 human studies support a reduced risk of colorectal cancer with ASA and NSAID use.
- Risk reduction observed in both men and women, for colon and rectal cancers.
- Findings are consistent across various NSAIDs and are unlikely due to earlier lesion detection from drug-induced bleeding.
Conclusions:
- Consistent epidemiological, clinical, and experimental data support the chemopreventive role of NSAIDs in colorectal cancer.
- No further placebo trials are necessary due to the strength of existing evidence.
- Research should now focus on establishing optimal dose, duration, and frequency for cancer prevention.